The experimental Novo Nordisk diabetes drug liraglutide has been found to be more efficient in helping people with diabetes to control blood sugar, when compared to older medicine .
58 per cent of diabetes patients who completed the trial using the Novo injectable medicine reached and maintained target blood glucose levels, compared to just 37 per cent who used glimepiride.
Dr. Alan Garber of the Baylor College of Medicine in Houston reportedly commented: “People overall lose weight with liraglutide. That’s a significant value-added benefit to this class of drugs . We were able to show that the safety risks of hypoglycemia are 10 times greater with the sulfonlyurea than with liraglutide because it has a completely different biochemical mechanism of action. To top it all off the blood sugar control with this agent is almost twice as good as with a maximum dose of what most people consider to be the best of the sulfonylureas.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…